Navigation Links
Abnormal EKG can predict death in stroke patients

People who suffer an ischemic stroke and also have an abnormality in the heart's electrical cycle are at a higher risk of death within 90 days than people who do not have abnormal electrical activity at the time of emergency treatment, according to new research.

The study also provides a threshold at which the threat of death is highest: QTc intervals greater than 440 milliseconds in women and 438 milliseconds in men have the worst prognosis. The findings are published online March 20, 2009, in the Journal of Stroke and Cerebrovascular Diseases.

"From a clinical perspective, our study offers additional parameters to consider while treating stroke patients in the Emergency Department setting,' said corresponding author Latha G. Stead, M.D., professor and chair of the Department of Emergency Medicine at the University of Rochester Medical Center, who recently joined the URMC from the Mayo Clinic. "It appears that reviewing the medications a patient is taking and looking specifically for those that might prolong the QTc interval would be a useful practice."

The QTc interval is a measure of the electrical activity of the heart. An EKG records the waves of activity and its pattern, which is labeled with letters Q and T. Doctors look for the appropriate intervals between each letter, showing that the heart's electrical signals are steadily passing through the ventricles. A prolonged QTc interval means it takes too long for the electrical signal to pass.

Prolonged QTc intervals can be the result of a rare genetic disorder, medications, electrolyte imbalances, or congenital heart disease. Scientific data on the relationship between abnormal QTc intervals and death has been inconsistent, and few studies have looked at this relationship in the context of acute ischemic stroke, Stead said.

Researchers studied the medical records of 345 ischemic stroke patients at the Mayo Clinic, treated between 2001 and 2004, and followed for 90 days. Further analysis was done to see if the researchers could identify a QTc cutoff that would accurately predict death within 90 days.

About 35 percent of the patients had a prolonged QTc interval at the time of the emergency department visit. An estimated 81 percent of all patients were expected to survive the next three months. However, results showed that only 70.5 percent of the patients with a prolonged QTc interval survived compared with 87.1percent of the patients without a prolonged QTc interval.

In addition, researchers found that although the causes of death ranged from stroke to cardiac illnesses to cancer and respiratory failure, most patients died of stroke or cardiac causes. In those cases, about half of the patients had prolonged QTc intervals. Among the stroke survivors, patients with prolonged QT intervals had poorer functional outcomes.

About 795,000 Americans each year suffer a new or recurrent stroke. That means, on average, a stroke occurs every 40 seconds, according to the American Stroke Association. Ischemic strokes, obstructions of the blood vessels supplying blood to the brain, account for the majority of cases.

Stead is supported by the Mayo Foundation Emergency Medicine Career Research Career Development Award.


Contact: Leslie Orr
University of Rochester Medical Center

Related medicine news :

1. Brain abnormality found in boys with attention deficit hyperactivity disorder
2. Abnormal Heart Rhythm Boosts Death Risk for Diabetics
3. Risk Score May Predict Abnormal Heart Rhythm
4. New Drug Shows Promise Against Heartbeat Abnormality
5. Rhythm abnormality of unknown origin strongly predicts sudden death risk in heart disease patients
6. Abnormal Heart Function Reduces Exercise Capacity
7. Gene abnormality found to predict childhood leukemia relapse
8. Decreased activity of basal ganglia is the main cause of abnormal muscle constrictions in dystonia
9. Molecular Breast Imaging Performs Better Than Ultrasound in Patients With Mammographic Abnormalities
10. Novel imaging technique reveals brain abnormalities that may play key role in ADHD
11. Scans Reveal Brain Abnormalities in Fibromyalgia Patients
Post Your Comments:
(Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
(Date:10/12/2017)... Malvern, PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best ... New York City on October 11, 2017. , The annual award competition recognizes editorial ...
(Date:10/12/2017)... ... ... On Saturday, October 21, the Health & Wellness Center at Florida Hospital ... for the American Heart Association Heart Walk. Teams of up to 10 people can ... their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on Saturday, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... nation's first interactive health literacy software tool, and the Cancer Patient Education Network ... cancer patient education, today announce a new strategic alliance. , As CPEN’s ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... 27, 2017  Commended for their devotion to personalized service, ... as number one in the South Florida Business Journal,s 50 ... 5000 yearly list, the national specialty pharmacy has found its ... will soon be honored by SFBJ as the 2017 ... Set to receive his award in October, Bardisa said ...
(Date:9/25/2017)... AMSTERDAM , Sept. 25, 2017   ... Trial Master File solutions, today—from the IQPC Trial ... Amsterdam , NL)—announced that EastHORN Clinical Services ... its clinical programs and TMF management. EastHORN, a ... Montrium,s eTMF platform to increase transparency to enable ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
Breaking Medicine Technology: